Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Enrolling by invitation 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

NET 2Gastrointestinal 2Endocrine 2

Conditions

Carcinoma, Non-Small-Cell Lung 767Lung Neoplasms 340Ovarian Neoplasms 318Breast Neoplasms 277Fallopian Tube Neoplasms 158Triple Negative Breast Neoplasms 144Small Cell Lung Carcinoma 142Neoplasms 134Squamous Cell Carcinoma of Head and Neck 122Carcinoma, Ovarian Epithelial 114Neoplasm Metastasis 85Head and Neck Neoplasms 80Endometrial Neoplasms 77Esophageal Neoplasms 71Uterine Cervical Neoplasms 70Adenocarcinoma of Lung 69Neuroblastoma 55Central Nervous System Neoplasms 52Carcinoma 50Lymphoma, Large B-Cell, Diffuse 49Brain Neoplasms 48Recurrence 47Prostatic Neoplasms 44Parkinson Disease 4, Autosomal Dominant Lewy Body 44Urinary Bladder Neoplasms 42Esophageal Squamous Cell Carcinoma 41Lymphoma 39Melanoma 35Carcinoma, Squamous Cell 33Lymphoma, Non-Hodgkin 31

Interventions

lutetium Lu 177 dotatate 6lanreotide 4Octreotide 4177Lu-octreotide, DOTA(0)-Tyr(3)- 4pasireotide 3copper dotatate CU-64 3gallium Ga 68 dotatate 2amino-acid, glucose, and electrolyte solution 2Temozolomide 2Nivolumab 2Magnetic Resonance Spectroscopy 2Lutetium-177 2Lutetium 2Irinotecan 2Ga(III)-DOTATOC 2Everolimus 2Etoposide 2Carboplatin 2zimberelimab 1regorafenib 1pembrolizumab 1irinotecan sucrosofate 1folfirinox 1famitinib 1cabozantinib 1arginyllysine 1abemaciclib 1X-Rays 1Sunitinib 1Somatostatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Gastro-enteropancreatic neuroendocrine tumor × Carboplatin × Clear all
NCT05385861 2025-08-15

Nal-IRI (ONIVYDE® ) and Carboplatin in Patients With Advanced or Metastatic GEP-NET

National Health Research Institutes, Taiwan

Phase 1/2 Enrolling by invitation
52 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor

NCT03980925 2025-01-13

Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.

Grupo Espanol de Tumores Neuroendocrinos

Phase 2 Completed
37 enrolled 25 charts
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡